With no approved antivirals or vaccines, the global market remains primarily supportive. Rising incidence—especially post‑2023 outbreaks—are increasing demand for diagnostics, symptomatic treatments, and surveillance. https://www.datamintelligence.com/research-report/oropouche-fever-market